Physician profile
Clyde A Epps
NPI 1174740138
$8,307.23
in general payments reported to CMS, 2019-2025
25 companies · $1,276 in 2025
The $1,276 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,788 · 2022: $1,576 · 2023: $1,878 · 2024: $1,789 · 2025: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,744 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.00 |
| Education | $199.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,641.53 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,086.63 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $733.84 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $716.35 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $524.61 | 2021-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $393.28 | 2021-2025 | |
| Alkermes, INC. | $384.80 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $299.96 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $258.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $246.02 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.38 | 2021-2025 | Caplyta |
| Lundbeck LLC | $176.27 | 2021-2024 | Rexulti |
| Eisai INC. | $150.16 | 2021 | |
| Supernus Pharmaceuticals, INC. | $87.74 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $84.69 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $67.27 | 2024-2025 | Auvelity |
| Noven Therapeutics, LLC | $45.45 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $33.16 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $31.08 | 2022 | |
| Noven Pharmaceuticals, INC. | $30.12 | 2022 | |
| Janssen Biotech, INC. | $28.86 | 2023 | |
| Abbott Laboratories | $23.67 | 2025 | Eterna |
| Lilly USA, LLC | $14.83 | 2025 | Mounjaro, Zepbound |
| Avanir Pharmaceuticals, INC. | $13.44 | 2021 | |
| Adlon Therapeutics L.P. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clyde Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.